Elite Pharmaceuticals Inc. ELTP
What this company does
Written from the business description in ELITE PHARMACEUTICALS INC /NV/'s annual report to the U.S. Securities and Exchange Commission, filed 29 June 2026. Every sentence was checked against that document before publication.
Revenue compounded at +42.4% a year over five years — but profit grew faster: net income at +54.6%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity produced 59 cents of profit this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 | · | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| Net income $B | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 |
| Free cash flow $B | 0.0 | 0.0 | −0.0 | −0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · |
| EPS, diluted $ | 0.03 | 0.00 | 0.02 | 0.00 | 0.01 | 0.00 | 0.00 | −0.01 | −0.01 | 0.01 | −0.01 | 0.02 | −0.21 | 0.00 | −0.06 | −0.14 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 58.9 | −7.8 | 46.5 | 13.1 | 43.0 | 38.0 | −55.0 | −899.3 | −24.3 | · | · | · | · | · | · | · |
| Shares out B | 1.08 | 1.07 | 1.07 | 0.00 | 1.01 | 1.01 | 0.84 | 0.82 | 0.80 | 0.93 | 0.71 | 0.63 | 0.56 | 0.37 | 0.33 | 0.18 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 17 of 19 fiscal years. 19 checks could not be computed.